Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Cone dystrophy with supernormal rod response (CDSRR) is an inherited retinopathy, with an onset in the first or second decade of life, characterized by poor visual acuity (due to central scotoma), photophobia, severe dyschromatopsia, and occasionally, nystagmus. Night blindness usually develops later in the course of the disease, but it can also be apparent from childhood. A hallmark of CDSRR is the decreased and delayed dark-adapted response to dim flashes in electroretinographic recordings, which contrasts with the supernormal b-wave response at the highest levels of stimulation.
Features include sometimes findings: Strabismus and Macular atrophy. 10 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Eyes | 3 | Strabismus, Macular atrophy, Horizontal nystagmus |
Muscles | 1 | Macular atrophy |
KCNV2 encodes potassium voltage-gated channel modifier subfamily V member 2 (545 aa). Potassium channel subunit. Modulates channel activity by shifting the threshold and the half-maximal activation to more negative values Highest expression in Testis (11.6 TPM) and Brain Cerebellum (0.9 TPM).
Cone dystrophy with supernormal rod response is associated with mutations in the KCNV2 gene on chromosome 9.
KCNV2 is classified as a druggable target (Druggable Genome, Ion Channel, and Transporter categories) with score 0.2.
Genetic testing for KCNV2 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for cone dystrophy with supernormal rod response has been reported in the published literature.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for cone dystrophy with supernormal rod response.
6 publications have been identified in PubMed for cone dystrophy with supernormal rod response. Research spans Case Report / Case Series (33%), Diagnostic / Biomarker (17%), and Basic Science / Preclinical (17%).
Hartmann S (2026). [PMID: 41844181](https://pubmed.ncbi.nlm.nih.gov/41844181/). *Klinische Monatsblatter fur Augenheilkunde*. [Diagnostic / Biomarker]
Busson SL (2025). [PMID: 41516321](https://pubmed.ncbi.nlm.nih.gov/41516321/). *International journal of molecular sciences*. [Gene Therapy / Novel Therapeutics]
Fatihoğlu ÖU (2025). [PMID: 41447038](https://pubmed.ncbi.nlm.nih.gov/41447038/). *Turkish journal of ophthalmology*. [Case Report / Case Series]
Alsalloum A (2024). [PMID: 39200733](https://pubmed.ncbi.nlm.nih.gov/39200733/). *Journal of clinical medicine*. [Case Report / Case Series]
Sakti DH (2024). [PMID: 38443311](https://pubmed.ncbi.nlm.nih.gov/38443311/). *Clinical & experimental ophthalmology*. [Epidemiology / Natural History]
Alsalloum A (2024). [PMID: 39083856](https://pubmed.ncbi.nlm.nih.gov/39083856/). *Stem cell research*. [Basic Science / Preclinical]
Data assembled from 6 of 12 sources · Last updated Sep 19, 2026, 10:22 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about cone dystrophy with supernormal rod response